GENE - Genetic highlights study suggesting geneType test's superiority in detecting breast cancer risk

2023-03-13 09:46:33 ET

Genetic Technologies ( NASDAQ: GENE ) said a research paper published in the journal Cancer Prevention Research supports the use of geneType Breast Cancer risk assessment test.

The paper titled, Validation of an abridged breast cancer risk prediction model for the general population, reported results from a study undertaken by the company's team in collaboration with John Hopper from the Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne.

The geneType breast cancer risk assessment test showed improved performance compared to a gold-standard model (BCRAT) over five years, according to the company.

The study used a prospective group of more than 200K women from the UK Biobank, the company noted.

Genetic said that over the five-year period, at-risk women classified ?3% 5-year risk by geneType had a 1.829 times increased incidence of breast cancer compared to the general population, which was higher than the 1.413 times increased incidence for women classified ?3% by BCRAT.

The company added that study showed that geneType not only put more women into an increased risk category but also showed women in this category developed breast cancer at a higher incidence.

"There are a significant number of women that are identified as at-increased risk by geneType and these same women 'fly under the radar' if traditional clinical models are used," said Erika Spaeth, Genetic's director of Clinical & Medical Affairs, and lead author on the paper.

For further details see: